ERBB2 and breast cancer: In vitro experiments revealed that CMTM6 mRNA and protein levels were the highest in the trastuzumab-resistant JIMT-1 (HER2+) BC cells and lower in the trastuzumab-sensitive SKBR3 and BT-474 BC cells.